Antigen-presenting cell (APC) subsets in ovarian cancer

International Reviews of Immunology

Volumn 30, Issue 2-3, 2011, Pages 120-126

  Wilke, Cailin Moira ^a   Kryczek, Ilona ^a   Zou, Weiping ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

B cells; B7 H1; B7 H4; macrophages; myeloid dendritic cells; Ovarian cancer; plasmacytoid dendritic cells; SDF 1; tumor associated macrophages

Indexed keywords

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL INTERACTION; CELL SUBPOPULATION; MYELOID DENDRITIC CELL; OVARY CANCER; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; MACROPHAGES; OVARIAN NEOPLASMS;

EID: 79955856003     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.567362     Document Type: Article

References (46)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252. (Pubitemid 28155090)
2. Schlienger K, Chu CS, Woo EY, et al. TRANCE-and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specifc for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9:1517-1527. (Pubitemid 36418410)
3. Santin AD, Hermonat PL, Ravaggi A, et al. In vitro induction of tumor-specifc human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601-609.
4. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ter 2009;9: 677-688.
5. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58. (Pubitemid 26028073)
6. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001;7:761-765. (Pubitemid 32691622)
7. Pardoll D. T cells and tumours. Nature 2001;411:1010-1012. (Pubitemid 32612311)
8. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-1103. (Pubitemid 26338628)
9. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-1346. (Pubitemid 34007939)
10. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitu-mor immunity. Nat Med 2003;9:562-567. (Pubitemid 36597102)
11. Steinbrink K, Wolf M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-4780. (Pubitemid 127471012)
12. Huarte E, Cubillos-RuizJR, Nesbeth YC, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008;68:7684-7691.
13. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of T17 cells in the human tumor environments. Blood 2009;114:1141-1149.
14. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949. (Pubitemid 39273735)
15. Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifes a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-881.
16. Wilke CM, Wu K, Zhao E, et al. Prognostic signifcance of regulatory T cells in tumor. Int J Cancer 2010;127:748-758.
17. Kryczek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67:8900-8905. (Pubitemid 47437467)
18. Wan T, Liu JH, Zheng LM, et al. [Prognostic signifcance of tumor-associated macrophage infltration in advanced epithelial ovarian carcinoma]. Ai Zheng 2009;28:323-327.
19. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-256.
20. Wilke CM, Kryczek I, Wei S, et al. T17 cells in cancer: Help or hindrance? Carcinogenesis 2011.
21. Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997;185:1101-1111. (Pubitemid 27136802)
22. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets diferentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64:5535-5538. (Pubitemid 39095544)
23. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020-5026. (Pubitemid 40827308)
24. Nelson BH. CD20+ B cells: The other tumor-infltrating lymphocytes. J Immunol 2010;185: 4977-4982.
25. Milne K, Kobel. M, Kalloger SE, et al. Systematic analysis of immune infltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009;4:e6412.
26. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6: 295-307.
27. Ziegler SF. FOXP3: Not just for regulatory T cells anymore. Eur J Immunol 2007;37:21-23. (Pubitemid 46128782)
28. Li Q, Teitz-Tennenbaum S, Donald EJ, et al. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009;183:3195-3203.
29. Hagn M, Schwesinger E, Ebel V, et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 2009;183:1838-1845.
30. Kemp TJ, Moore JM, Grifth TS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 2004;173:892-899. (Pubitemid 38924262)
31. Lundy SK. Killer B lymphocytes: The evidence and the potential. Infamm Res 2009.
32. Dong HP, Elstrand MB, Holth A, et al. NK-and B-cell infltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006;125:451-458. (Pubitemid 43327717)
33. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-Specific antigen. J Immunol 1980;125:1678-1685. (Pubitemid 10018582)
34. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci USA 1981;78:3848-3852. (Pubitemid 11060476)
35. Rosenthal P, Rimm IJ, Umiel T, et al. Ontogeny of human hematopoietic cells: Analysis utilizing monoclonal antibodies. J Immunol 1983;131:232-237. (Pubitemid 13067886)
36. Nadler LM, Anderson KC, Marti G, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983;131:244-250. (Pubitemid 13067888)
37. Watt V, Ronchese F, Ritchie D. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother 2007;30:323-332. (Pubitemid 46586648)
38. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005;238:67-75.
39. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-482.
40. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008;20:332-338.
41. Deola S, Panelli MC, Maric D, et al. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 2008;180:1362-1372.
42. Whitmire JK, Asano MS, Kaech SM, et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol 2009;182:1868-1876.
43. Yanaba K, Bouaziz JD, Matsushita T, et al. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223:284-299. (Pubitemid 351986191)
44. Couper KN, Blount DG, Riley EM. IL-10: The master regulator of immunity to infection. J Immunol 2008;180:5771-5777.
45. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: A counterpoint. J Leukoc Biol 2005;78:1043-1051. (Pubitemid 41572467)
46. Murai M, Turovskaya O, Kim G, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009;10:1178-1184.